Forest Labs files for approval of depression drug
NEW YORK - Forest Laboratories Inc. said Thursday it filed for marketing approval of its depression drug levomilnacipran. Forest and its partner Pierre Fabre...
View ArticleForest Laboratories (FRX) Submits New Drug Application for Levomilnacipran...
Tweet FRX Hot Sheet Price: $35.91 --0% Overall Analyst Rating: NEUTRAL ( Down) Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories today announced that Forest has submitted a New Drug...
View ArticleForest Laboratories Submits New Drug Application for Levomilnacipran for the...
Forest Laboratories Submits New Drug Application for Levomilnacipran for the Treatment of Major Depressive Disorder NEW YORK & CASTRES, France--(BUSINESS WIRE)-- Forest Laboratories, Inc. (NYS:...
View ArticleForest Laboratories Submits New Drug Application for Levomilnacipran for the...
NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S....
View ArticleForest Laboratories Submits New Drug Application for Levomilnacipran for the...
Tweet FRX Hot Sheet Price: $35.91 -0.53% Overall Analyst Rating: NEUTRAL ( Down) NEW YORK & CASTRES, France--(BUSINESS WIRE)-- Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories...
View ArticleLaboratoires Pierre Fabre Relies on Manhattan Associates to Increase Supply...
(Source: Manhattan Associates Inc) PARIS and ATLANTA - April 2, 2013- Global supply chain optimization provider, Manhattan Associates, Inc. (NASDAQ: MANH), today announced that global pharmaceutical...
View ArticleForest Laboratories, Inc. to Present Data from Cariprazine and...
Forest Laboratories, Inc. (NYSE: FRX), today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA)...
View ArticleForest Laboratories, Inc. to Present Data from Cariprazine and...
(Source: Forest Laboratories Inc) NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), today announced it will be presenting data on two late-stage development products, cariprazine and...
View ArticleForest Laboratories, Inc. to Present Data from Cariprazine and...
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American...
View ArticleADDING MULTIMEDIA: Forest Laboratories and Pierre Fabre Laboratories...
(Source: Forest Laboratories Inc) NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories announced today that FETZIMA™ (levomilnacipran...
View ArticleForest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of...
(Source: Forest Laboratories Inc) NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories announced today that FETZIMA™ (levomilnacipran...
View ArticleForest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of...
NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories announced today that FETZIMA™ (levomilnacipran extended-release capsules), a...
View ArticleForest Announces New FETZIMA™ (levomilnacipran ER capsules) Now Available in...
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United States. FETZIMA was...
View ArticlePierre Fabre Obtains FDA Approval to Market HemangeolTM for the Treatment of...
CASTRES, France & PARSIPPANY, N.J.--(BUSINESS WIRE)--Pierre Fabre Dermatologie has obtained marketing authorization from the FDA* for the pediatric drug HemangeolTM (propranolol hydrochloride),...
View ArticleForest Laboratories, Inc. to Present Data about Levomilnacipran and...
Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio, levomilnacipran and vilazodone, at the American Psychiatric...
View ArticleForest Laboratories, Inc. to Present Data about Levomilnacipran and...
(Source: Forest Laboratories Inc) NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio,...
View ArticleForest Laboratories, Inc. to Present Data about Levomilnacipran and...
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data from its Major Depressive Disorder (MDD) portfolio, levomilnacipran and vilazodone, at the...
View ArticleForest Laboratories and Cypress announce submission of new drug application...
05:01:02 AM EST CHEMICAL BUSINESS NEWSBASE - PRESS RELEASE Forest Laboratories Inc and Cypress Bioscience Inc (Cypress) have recently submitted a New Drug Application (NDA) to the US Food and Drug...
View ArticleNPIL Nears Deal With French Pharma Major
MUMBAI, JUNE 6: Pharmaceutical major Nicholas Piramal India Ltd (NPIL) is all set to seal an agreement with one of the largest pharmaceutical players in France -- Pierre Fabre Group. The company is...
View ArticleCypress Bioscience Inc. Announces Final Results of Milnacipran Phase II...
6:31am > CHICAGO--(BUSINESS WIRE)---- Milnacipran Shown to Produce Improvement on Primary and Secondary Clinical Trial Endpoints Cypress Bioscience Inc. (NASDAQ:CYPB) today announced that its lead...
View ArticleCypress Bioscience Revises Milnacipran License With Pierre Fabre Medicament...
6/9/03 SAN DIEGO, Jun 9, 2003 /PRNewswire-FirstCall via COMTEX/ -- Cypress Bioscience, Inc. (Nasdaq: CYPB) announced today that it has modified its Milnacipran license agreement with Pierre Fabre...
View ArticleMILLENIA HOPE INCQuick Quote:
0.06 (Even) Laboratoires Pierre Fabre and Millenia Hope Biopharma Enter Into an Important Collaborative Partnership 6/22/2006 CASTRES, France, and WILMINGTON, Del., June 22, 2006 /PRNewswire via COMTEX...
View ArticlePierre Fabre Médicament recibe la autorización en Australia para...
CASTRES, , November 21, 2011 /PRNewswire/ -- - Pierre Fabre Médicament recibe la autorización en para comercializar Milnacipran JONCIA® para tratar la fibromialgia La Therapeutic Goods Administration...
View ArticleLaboratoires Pierre Fabre and Millenia Hope Biopharma Enter Into an Important...
CASTRES, France, and WILMINGTON, Del., June 22 /CNW/ -- Les Laboratoires Pierre Fabre, a privately held company, and Millenia Hope Inc., a Biopharma Corporation (OTC Bulletin Board: MLHP), are pleased...
View ArticlePierre Fabre Laboratories Selects Dassault Systèmes’ Version 6 Platform to...
Leading Pharmaceutical and Dermo-cosmetics Group Replaces Most of its Existing Product Development Applications with Single PLM Platform; Develop more cross-cutting activities, improve time to market...
View ArticleA phase II/III clinical data published in the NEJM confirms positive...
PARSIPPANY, N.J., Feb. 20, 2015 /PRNewswire/ -- Pierre Fabre announced today that the results from the landmark clinical trial evaluating the first ever pediatric propranolol treatment for use in...
View ArticleSales of Dermo-Cosmetics on the Internet: Ruling by the EU Court of Justice...
CASTRES, , October 13, 2011 /PRNewswire/ -- Pierre Fabre Laboratories have been opposed to the sale of dermo-cosmetic products on the Internet for many years. The Laboratories have argued that only...
View ArticleCypress Bioscience Inc. Announces New Milnacipran Manufacturing Facility in...
7/20/04 SAN DIEGO, Jul 20, 2004 (BUSINESS WIRE) -- Cypress Bioscience Inc. (NASDAQ:CYPB) announced today that Pierre Fabre (milnacipran's originator) plans to set up a second milnacipran production...
View ArticleForest Laboratories and Cypress Bioscience Announce Study Shows Patients...
Phase III Data to be Presented at American College of Rheumatology Annual Meeting Further Demonstrate Efficacy and Safety of Savella for the Management of Fibromyalgia NEW YORK & SAN DIEGO, Oct 17,...
View ArticleForest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised...
NEW YORK and SAN DIEGO, March 6, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced today that they...
View ArticleForest and Cypress Announce FDA Approval of Savella(TM) for the Management of...
NEW YORK and SAN DIEGO, Jan. 14, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- New treatment option for the estimated 6 million Americans living with this chronic, debilitating condition...
View ArticlePierre Fabre Medicament and Forest Laboratories to Collaborate on Development...
Distributed by Press Release EMAIL ARTICLE PRINT ARTICLE NEW YORK and PARIS, Dec. 22, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced...
View ArticlePierre Fabre Médicament is Granted Authorisation in Australia to Market the...
CASTRES, France, Nov. 21, 2011 /CNW/ - The Therapeutic Goods Administration (TGA), Australia's regulatory body for therapeutic products, granted Pierre Fabre Médicament's milnacipran market...
View ArticleForest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results...
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American...
View ArticleForest Laboratories, Inc. and Pierre Fabre Medicament Announce Topline Phase...
NEW YORK & PARIS - Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of...
View ArticleForest Laboratories, Inc. and Pierre Fabre Medicament Announce Positive Phase...
NEW YORK & PARIS--(BUSINESS WIRE)-- Forest Laboratories, Inc. (NYSE: ) and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the...
View ArticleForest Laboratories, Inc. and Pierre Fabre Medicament Announce Positive Phase...
NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced positive top-line results in a Phase III clinical trial of...
View ArticleForest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive...
NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced additional positive results from a Phase III clinical trial of...
View ArticleAbCheck and Pierre Fabre Pharmaceuticals Enter Into Strategic Research...
PLZEN, Czech Republic and CASTRES, France, June 17, 2015 (GLOBE NEWSWIRE) -- AbCheck s.r.o, a wholly owned subsidiary of Affimed N.V., Heidelberg, Germany, and Pierre Fabre Pharmaceuticals announced...
View ArticlePierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage...
(Source: Addex Therapeutics Ltd) Pierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage Agreement in the Central Nervous System (CNS) Field Addex Grants Option to License mGlu3 Receptor...
View Article
